LOGIN  |  REGISTER
Assertio

Kura Oncology (NASDAQ: KURA) Stock Quote

Last Trade: US$19.48 -0.92 -4.51
Volume: 619,533
5-Day Change: -4.32%
YTD Change: 35.47%
Market Cap: US$1.480B

Latest News From Kura Oncology

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2024 Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. ET /... Read More
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options... Read More
Company anticipates dosing of KO-2806 in combination with adagrasib in KRAS G12C -mutant NSCLC next quarter Dose escalation of KO-2806 as a monotherapy continues in parallel SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dosing of the first... Read More
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options... Read More
Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome First patient dosed in KOMET-008 trial of ziftomenib in combination with additional standards of care, including gilteritinib, FLAG-IDA and LDAC, in AML Completion of enrollment in registration-directed trial of ziftomenib in NPM1-m AML anticipated by mid-2024 $570... Read More
KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in... Read More
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences: A fireside chat at the TD Cowen Health Care conference in... Read More
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura’s management will host a webcast and conference... Read More
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock... Read More
No differentiation syndrome events reported 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML 80% of patients remain on trial as of data cutoff, including all NPM1-m patients 200 mg dose of ziftomenib cleared in ven/aza cohorts, enrollment at 400 mg dose ongoing Management to host virtual investor event today at 8:00 a.m. ET SAN DIEGO, Jan.... Read More
Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital Pro forma cash, cash equivalents and investments expected to provide runway into 2027 Management to host virtual investor event at 8:00 a.m. ET on January 30 to highlight preliminary combination data for ziftomenib SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage... Read More
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy... Read More
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit at 2:00 p.m. ET / 11:00... Read More
Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarter of 2024 First patient dosed in FIT-001 dose-escalation study of next-generation FTI, KO-2806 Clinical collaboration with Mirati to evaluate KO-2806 and adagrasib in KRAS G12C -mutated NSCLC... Read More
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation... Read More
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences. A virtual fireside chat at the TD Cowen Fall Oncology... Read More
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m.... Read More
Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRAS G12C -mutant NSCLC and ccRCC SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in the FIT-001... Read More
Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806 into combinations with targeted therapies in large solid tumor indications Results to be presented in late-breaking oral session at 2023 ESMO Congress on Saturday SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.... Read More
Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRAS G12C inhibitors and KRAS G12 D inhibitors SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts have been... Read More
Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRAS G12C inhibitors Company to include KRAS G12C -mutant NSCLC in combination portion of Phase 1 clinical trial of KO-2806 (FIT-001) SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the... Read More
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare Conference 2023 being held in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a... Read More
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing... Read More
Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC First-in-human study of... Read More
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2023 financial results after the close of U.S. financial markets on Thursday, August 3, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m.... Read More
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. Kura is selling 5,660,871 shares of its common stock and pre-funded warrants to purchase 3,034,782 shares of its... Read More
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $100,000,000 of shares of its common stock (or pre-funded warrants to purchase its... Read More
35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib Ziftomenib monotherapy drives durable remissions, with median DoR of 8.2 months Data suggest ziftomenib is less likely to induce menin resistance mutations Enrollment in Phase 2 registration-directed... Read More
Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 Data from Phase 1 trial of ziftomenib to be presented at the late-breaking oral session on Sunday, June 11, 2023 Management to host virtual investor event at 8:00 a.m. ET on Monday, June 12, 2023 SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company... Read More
SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences: A fireside chat at the virtual TD Cowen 4th... Read More
Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML to dose first patients in the second quarter of 2023 Preclinical data highlighting potential use of FTIs in combination with... Read More
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 11:00... Read More
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m. ET /... Read More
SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2023 Targeted Oncology Days. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:00 p.m. ET / 10:00... Read More
Preclinical data support the potential for FTIs in combination with KRAS G12C inhibitors and TKIs to prevent or delay emergence of adaptive resistance Company preparing to initiate Phase 1 dose-escalation trial (FIT-001) of KO-2806, a next-generation FTI SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision... Read More
Presentations to highlight preclinical data supporting combination of FTIs with KRAS G12C inhibitors and tyrosine kinase inhibitors SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the... Read More
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences: A “Leukemia Corporate Panel” discussion at... Read More
Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on track to initiate in first half of 2023 IND for KO-2806, a next-generation farnesyl transferase inhibitor, cleared by FDA $25... Read More
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023. Kura’s management will host a webcast and conference call at... Read More
Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the... Read More
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 5:00 p.m.... Read More
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the... Read More
30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive Type C meeting with FDA Company expects to dose first patient in Phase 2 registration-directed trial in NPM1-mutant AML in... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB